查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015231

全球医药契约製造市场：2026-2032年市场预测（依服务类型、分子类型、剂型、治疗领域、合约类型、生产规模及製程划分）

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年，医药契约製造市场价值1,522.7亿美元，预计到2026年将成长至1,647.1亿美元，复合年增长率为10.06%，到2032年将达到2978.8亿美元。

主要市场统计数据
基准年 2025 1522.7亿美元
预计年份：2026年 1647.1亿美元
预测年份 2032 2978.8亿美元
复合年增长率 (%) 10.06%

权威说明指出，契约製造已从单纯的成本削减措施转变为支持医药创新和供应链韧性的策略职能。

医药契约製造产业在全球医药供应链中扮演着至关重要的角色，它使创新公司、学名药生产商和生物相似药开发商能够将突破性的实验室成果转化为可扩展且符合监管规定的商业产品。外包生产、製剂开发、分析测试和包装已不再只是降低成本的手段，而是发展成为一种战略能力，有助于加快产品上市速度、提高产品组合的柔软性并分散风险。如今，整个价值链上的相关人员不再仅仅将契约製造视为产能供应商，而是将其视为共同承担技术风险管理、合规性和生命週期管理责任的合作伙伴。

技术进步、更严格的监管和地缘政治压力如何共同作用，重新定义契约製造能力和策略采购模式。

近年来，在技术进步、监管日益复杂以及相关人员期望不断变化的推动下，支持药物研发和商业化的契约製造模式正在迅速重塑。先进生物製药和细胞/基因疗法的兴起迫使合约生产机构（CDMO）投资于无菌注射和低温运输平台。同时，连续生产和製程整合正在改变生产经济效益和设施设计框架。这些变化并非孤立存在，而是同时重塑整个产业的商业性采购模式、资本规划和人才需求。

了解将于 2025 年实施的美国新关税对营运和商业的广泛影响，以及这些关税将如何重组采购、投资和合约策略。

美国2025年实施的关税政策调整，为药品原料、包装材料和资本设备的采购计算增加了新的复杂性，迫使契约製造生产商及其委託客户重新审视成本结构和供应风险模型。某些进口材料和设备的关税提高，导致无菌填充所需组件、专用包装材料和先进分析仪器的到货成本上升。这一趋势正在影响从研发到商业化的整个流程。临床供应预算受到挤压，新设施和设备的资本投资计划被迫修订，委託方和合约研发生产机构（CDMO）之间的价格谈判必须反映原材料成本波动加剧的情况。

策略性細項分析揭示了服务、分子、剂型、客户类型、治疗领域、合约模式、生产规模和製程选择方面的能力需求。

精细的細項分析揭示了服务类型、分子类别、剂型、客户类型、治疗领域、合约模式、生产阶段和製程设计方案等方面的能力差距和策略重点的交汇点。服务专长涵盖分析服务（包括生物分析、法律架构制定和稳定性测试）；研发服务（包括製剂和製程开发）；灌装服务（包括注射器、单剂量製剂和管瓶灌装）；生产服务（包括口服液体製剂、口服固态製剂、无菌注射剂和外用製剂）；以及一级包装和标籤服务（满足一级包装需求）。每个服务领域所需的资本投入、监管路径和技术专长各不相同。能够无缝协调研发、分析表征和商业化生产各个阶段的公司，能够为委託公司带来缩短产品上市时间的实际效益。

美洲、欧洲、中东和非洲以及亚太地区的区域生产能力、监管复杂性和战略奖励如何影响製造地地点和采购决策？

区域趋势决定了产能的布局、供应风险管理方式以及影响商业性决策的监管节点。在美洲，对无菌注射剂、先进的生物製药灌装和包装以及安全供应链的需求正在推动对国内产能和专业领域的投资。该地区监管清晰、市场庞大，且接近性主要赞助商公司的总部，因此对寻求更短前置作业时间和更快技术合作的近岸外包企业和赞助商公司都极具吸引力。

深入了解能力整合、平台专业化和深度客户伙伴关係如何重塑契约製造供应商的竞争地位。

领先的契约製造和服务供应商之间的竞争格局呈现出能力整合、平台差异化以及超越单纯交易关係的更深层客户伙伴关係的特征。许多公司正透过提供从研发到商业化的一体化解决方案，向价值链上游移动，从而减少技术转移的阻力并加快商业化进程。这一趋势体现在以下方面：分析平台的扩展以支持复杂的生物製药；对无菌灌装和包装能力的投资；以及采用数位化品管和生产执行系统以实现更可预测的结果。

为製造商和赞助商提供切实可行的策略行动，以提高柔软性、降低供应风险，并使商业性框架适应不断变化的生产实际情况。

产业领导企业应优先采取一系列战术性和策略措施，将当前的市场动态转化为永续的竞争优势。首先，应有选择地投资于模组化和灵活的生产平台，这些平台能够处理多种剂型和分子种类，从而实现专案间的快速部署，并减少因设备更换而造成的时间损失。整合强大的分析技术和数位化製程控制将有助于实现品质源自于设计 (QbD) 的理念，并促进从临床到商业化生产的平稳过渡。

透过与关键相关人员的访谈、文件检验和基于情境的压力测试，采用严谨的混合研究途径，获得了可靠的策略见解。

本分析的研究结合了对行业相关人员的结构化一手访谈、对二手资讯的严格整合以及基于情景的供应链压力测试，以确保得出切实可行且令人信服的见解。一手访谈对象包括来自不同赞助公司和契约製造组织 (CMO) 的研发科学、品质保证、法规事务、采购和营运部门的高阶领导。这些对话重点在于能力差距、近期投资、技术转移经验以及应对政策和供应链中断的实际措施。

简要概述能力整合、供应多元化和现代合约形式如何塑造契约製造中相互竞争的韧性支柱。

受技术、监管、商业性和地缘政治因素的影响，製药生产的合约和营运框架正在快速变化。投资于平台多功能性、高级分析和数位化控制的契约製造製造商将更有能力满足生技药品和小分子药物申办方的复杂需求。策略采购选择，包括近岸外包和供应商多元化，是管理成本和业务永续营运风险的关键工具，尤其是在贸易政策变化可能对投入成本产生重大影响的环境下。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：药品契约製造市场：依服务类型划分

  • 分析服务
    • 生物分析服务
    • 方法开发
    • 稳定性测试
  • 发展服务
    • 配方开发
    • 製程开发
  • 填充服务
    • 注射器填充
    • 单剂量补充装
    • 管瓶填充
  • 製造服务
    • 液体
    • 固态口服药物
    • 无菌注射剂
    • 外用製剂
  • 包装和标籤
    • 初级包装
    • 二级包装

第九章：药品契约製造市场：依分子类型划分

  • 生物製药
  • 小分子药物

第十章：药品契约製造市场：依剂型划分

  • 液体
    • 口服液
    • 悬浮液
  • 固态剂型
    • 胶囊
    • 药片
  • 无菌注射剂
  • 外用製剂
    • 乳膏和软膏
    • 凝胶

第十一章：药品契约製造市场：依治疗领域划分

  • 循环系统
  • 中枢神经系统
  • 感染疾病
  • 肿瘤学

第十二章：药品契约製造市场：依合约类型划分

  • 独家的
  • 非独家

第十三章：医药契约製造市场：依生产规模划分

  • 临床试验
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的

第十四章：药品契约製造市场：依工艺划分

  • 批次
  • 连续型

第十五章：医药契约製造市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：药品契约製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 药品契约製造市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国：药品契约製造市场

第十九章 中国：医药契约製造市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Cambrex Corporation
  • Catalent, Inc.
  • Fujifilm Diosynth Biotechnologies US, LLC
  • Lonza Group AG
  • PCI Pharma Services, Inc.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-030EE48515DD

The Pharmaceutical Contract Manufacturing Market was valued at USD 152.27 billion in 2025 and is projected to grow to USD 164.71 billion in 2026, with a CAGR of 10.06%, reaching USD 297.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 152.27 billion
Estimated Year [2026] USD 164.71 billion
Forecast Year [2032] USD 297.88 billion
CAGR (%) 10.06%

An authoritative orientation to how contract manufacturing has transformed from a cost-driven option into a strategic capability for pharmaceutical innovation and supply resilience

The pharmaceutical contract manufacturing arena occupies a pivotal role in the global medicines supply chain, enabling innovators, generics players, and biosimilar developers to translate laboratory breakthroughs into scalable, regulated commercial products. Outsourcing of production, formulation development, analytical testing, and packaging has evolved from a cost containment tactic into a strategic capability that supports speed to market, portfolio flexibility, and risk diversification. Stakeholders across the value chain now view contract manufacturing organizations as partners that co-own technical risk, compliance pathways, and lifecycle management responsibilities rather than as mere capacity vendors.

Today's landscape is shaped by converging pressures: complex biologic modalities that require specialized sterile and cold-chain capabilities; regulatory expectations for robust quality systems and supply traceability; and commercial demands for faster clinical-to-commercial transitions. These dynamics have elevated the importance of integrated service models that combine development expertise, analytical depth, and commercial-scale manufacturing. Consequently, forward-looking sponsors prioritize long-term technical relationships, modular manufacturing footprints, and transparency in supply risk, positioning contract manufacturers as central nodes in pharmaceutical innovation and distribution strategies.

How technological advances, regulatory tightening, and geopolitical pressures are converging to redefine contract manufacturing capabilities and strategic sourcing models

Recent years have seen a rapid reshaping of how contract manufacturing supports drug development and commercialization, driven by technological advances, regulatory complexity, and evolving stakeholder expectations. The rise of advanced biologics and cell and gene therapies has pushed CDMOs to invest in sterile injectables and cold chain platforms, while continuous manufacturing and process intensification have begun to reframe production economics and facility design. These shifts are not isolated; they simultaneously reshape commercial sourcing models, capital planning, and talent requirements across the industry.

Regulators globally are reinforcing expectations for quality-by-design, process robustness, and supply chain transparency, prompting manufacturers and their partners to embed analytics and digital thread capabilities across development and production lifecycles. Meanwhile, the industry's geographic footprint is adapting to geopolitical and trade developments, with localized capacity, dual-sourcing strategies, and nearshoring gaining prominence as mechanisms to mitigate disruption. Taken together, these transformative currents favor contract manufacturers that can demonstrate platform standardization, cross-modal expertise, and an agile approach to integrating regulatory, technical, and commercial needs into cohesive delivery models.

Understanding the broad operational and commercial consequences of new United States tariff measures in 2025 and how they reshape sourcing, investment, and contractual strategies

The tariff policy adjustments implemented by the United States in 2025 have introduced a new layer of complexity into the sourcing calculus for pharmaceutical ingredients, packaging components, and capital equipment, compelling both contract manufacturers and their sponsor customers to revisit cost structures and supply risk models. Increased duties on certain imported materials and equipment have translated into higher landed costs for components essential to sterile filling, specialized packaging substrates, and sophisticated analytical instrumentation. This dynamic has consequences across the development-to-commercial continuum: clinical supply budgets are pressured, capital expenditure plans for new facilities or equipment require recalibration, and pricing discussions between sponsors and CDMOs must account for elevated input cost volatility.

Beyond the direct cost impact, the tariffs have accelerated strategic behaviors that alter long-term industry structure. Some sponsors have prioritized re-shoring or near-shoring initiatives to reduce exposure to trade friction, which in turn increases demand for domestic capacity in steriles, biologics fill-finish, and specialized packaging. Contract manufacturers with flexible production models and multi-jurisdictional footprints have found increased interest from customers seeking rapid contingency options and shorter logistics chains. At the same time, suppliers of raw materials located in tariff-affected geographies are exploring re-certification pathways, dual-sourcing arrangements, and tariff-engineering solutions to preserve competitiveness.

The cumulative effect of these policy changes extends to supplier negotiations and commercial contracting. Cost escalation clauses, pass-through mechanisms, and inventory financing arrangements have become focal points of new contracts. Sponsors and CDMOs are seeking greater transparency on bill-of-materials composition and origin, and are more frequently agreeing to longer-term procurement commitments to secure stable pricing. Moreover, regulatory authorities and industry groups have engaged in dialogue about maintaining supply continuity for essential medicines, which has encouraged stakeholders to develop contingency playbooks that combine strategic stockpiles, multiple manufacturing sites, and prioritized allocation frameworks for critical components.

In sum, tariffs enacted in 2025 function less as a temporary price shock and more as a catalyst for structural change: they have shifted sourcing strategies toward resilience and localization, elevated the value of manufacturing flexibility, and forced sharper alignment between commercial terms and supply chain realities. Organizations that proactively integrate tariff risk into scenario planning, capital investment decisions, and supplier governance will be better positioned to sustain supply continuity and preserve margins while maintaining compliance and product quality.

Strategic segmentation analysis revealing capability demands across services, molecules, dosage forms, customer archetypes, therapeutic focuses, contract models, production scales, and process choices

A nuanced segmentation view reveals where capability gaps and strategic priorities converge across service modalities, molecule classes, dosage formats, customer archetypes, therapeutic focus, contract models, production phases, and process design choices. Service-type specialization spans analytical services that cover bioanalytical work, method development, and stability studies; development services that encompass formulation and process development; filling services that include syringe, unit dose, and vial filling; manufacturing services oriented to liquid orals, solid oral dosage, sterile injectables, and topical formulations; and packaging and labeling services that address primary and secondary packaging needs. Each service strand demands distinct capital intensity, regulatory pathways, and technical competencies, and firms that can offer integrated handoffs between development, analytical characterization, and commercial manufacturing create tangible time-to-market advantages for sponsors.

Molecule type drives technical complexity and facility requirements. Biologics require specialized upstream and downstream processing, cold chain considerations, and sterile handling regimes, while small molecules often align with established solid oral or liquid oral manufacturing platforms. Dosage form segmentation further refines capability needs: liquid dosage formats including oral solutions and suspensions necessitate excipient sourcing and stability expertise; solid dosage capsules and tablets demand robust formulation development and compression/fill capabilities; sterile injectables impose stringent aseptic practices and validated fill-finish suites; and topical dosage forms such as creams, ointments, and gels require formulation rheology control and container compatibility testing.

Customer type and therapeutic area shape commercial engagement models. Biosimilar manufacturers often seek high-volume commercial capacity and regulatory comparability expertise, generic manufacturers prioritize rapid scale-up and cost-efficient tooling, and innovator manufacturers demand integrated development pathways and controlled tech transfer. Therapeutic focus areas, such as cardiovascular, central nervous system, infectious diseases, and oncology, impose differing requirements for clinical supply chain timing, packaging and labeling complexity, and regulatory interaction intensity. Contract type and production scale introduce governance and utilization dynamics: dedicated contracts provide capacity assurance and long-term alignment, whereas non-dedicated models offer flexibility but require more complex scheduling. Clinical-scale production, with phase-specific needs across Phase I, II, and III, requires nimble tech transfer and batch documentation practices that differ materially from commercial-scale operations. Finally, process type-batch versus continuous-affects capital deployment, process monitoring complexity, and implications for scale-up. Continuous processes can enable higher throughput and more consistent product quality for certain modalities but require a higher level of process control and real-time analytical capabilities. Mapping capabilities against these segmentation axes allows stakeholders to identify where to consolidate partnerships, where to invest in capability development, and where to prioritize risk mitigation to support therapeutic and commercial objectives.

How regional capacity, regulatory complexity, and strategic incentives in the Americas, Europe Middle East & Africa, and Asia-Pacific shape manufacturing footprints and sourcing decisions

Regional dynamics are shaping where capacity is built, how supply risk is managed, and which regulatory touchpoints dominate commercial considerations. In the Americas, demand for sterile injectables, advanced biologics fill-finish, and secure supply chains has driven investments in domestic capacity and specialization. This region's combination of regulatory clarity, large commercial markets, and proximity to major sponsor headquarters makes it attractive for nearshoring initiatives and for sponsors seeking shorter lead times and more responsive technical collaboration.

Europe, Middle East & Africa represents a diverse regulatory and capability landscape where established CDMOs co-exist with niche innovators. European manufacturing networks often emphasize harmonized regulatory pathways and advanced process technologies, while countries across the broader region offer differentiated cost structures and emerging specialized capabilities. Cross-border regulatory alignment within this region influences where multicountry batch release strategies and centralized quality oversight are implemented, which affects the design of multi-site manufacturing networks.

Asia-Pacific continues to be a critical capacity hub, offering broad manufacturing bases for small molecules, generics, and an expanding footprint for biologics and sterile manufacturing. The region's competitive cost profile, deep supplier networks for excipients and packaging materials, and growing technical talent pool make it a central node for both clinical and commercial production. Simultaneously, increasing regulatory sophistication in several Asia-Pacific markets and rising domestic demand are pushing local providers to upgrade quality systems and to pursue international certifications, which in turn broadens the set of viable sourcing options for global sponsors.

Across these geographies, supply chain resilience, regulatory convergence efforts, and strategic incentives for local manufacturing are the common themes influencing investment decisions. Sponsors and contract manufacturers must evaluate trade-offs between cost, lead time, regulatory complexity, and risk exposure when configuring global footprints; the optimal approach increasingly blends regional centers of excellence with redundant capacity and rapid-response capabilities.

Insights into how capability consolidation, platform specialization, and deep client partnerships are reshaping competitive positioning among contract manufacturing providers

Competitive dynamics among leading contract manufacturers and service providers are characterized by capability consolidation, platform differentiation, and deeper client partnerships that extend beyond transactional engagements. Many firms are moving up the value chain by offering integrated development-to-commercial solutions that reduce tech transfer friction and accelerate commercialization timelines. This trend is visible in the expansion of analytical platforms that support complex biologics, investments in sterile fill-finish capacity, and the adoption of digital quality and manufacturing execution systems to enable more predictable outcomes.

Strategic partnerships, mergers, and targeted greenfield investments are being used to expand modality coverage and geographic presence, while mid-sized specialized players often succeed by focusing on niche capabilities such as high-potency handling, complex packaging, or rapid-turn clinical supply. For sponsors, the choice of partner reflects a balance between scale, technical specialization, and the depth of regulatory experience. Increasingly, procurement teams value partners who can demonstrate demonstrable process ruggedness, a track record of successful tech transfers, and transparent governance over multi-supplier supply chains.

Talent and leadership continuity are notable differentiators. Organizations that retain cross-functional teams covering development sciences, regulatory affairs, quality assurance, and operational excellence are better equipped to navigate complex projects and minimize time-to-release delays. Additionally, firms that provide clear roadmaps for capacity expansion and contingency management tend to attract longer-term commitments from customers seeking to de-risk their product launches and lifecycle supply.

Practical strategic actions for manufacturers and sponsors to enhance flexibility, mitigate supply risks, and align commercial frameworks with evolving production realities

Industry leaders should prioritize a series of tactical and strategic actions to convert current market dynamics into sustainable advantage. First, invest selectively in modular and flexible manufacturing platforms that can accommodate multiple dosage forms and molecule classes, thereby enabling rapid redeployment across projects and reducing time lost to retooling. Embedding robust analytical technologies and digital process controls will support quality-by-design approaches and facilitate smoother scale-up pathways from clinical to commercial production.

Second, re-evaluate supplier and sourcing strategies to mitigate tariff exposure and logistical risk. This includes diversifying input suppliers, negotiating clearer pass-through clauses, and developing nearshore alternatives where feasible. Transparent supply-of-origin documentation and a proactive approach to supplier qualification will improve negotiating leverage and reduce downstream surprises.

Third, strengthen integrated development pathways by co-locating or tightly coordinating formulation, analytical, and process development teams with manufacturing operations. This alignment shortens feedback loops, accelerates tech transfer, and reduces regulatory friction at the point of scale-up. Complementary to this, establish formal contingency playbooks for critical material shortages and regulatory delays, including prioritized allocation criteria and pre-agreed surge capacity arrangements with trusted partners.

Fourth, adopt outcome-oriented commercial models with customers, such as milestone-linked pricing and risk-sharing arrangements, to better align incentives and accommodate input cost volatility. Develop contract frameworks that include clear escalation mechanisms for input cost shocks while preserving collaborative governance for change management. Finally, prioritize talent development programs that cross-train scientists, quality professionals, and operations staff to build institutional resilience and reduce dependency on single individuals or teams during critical transfer phases.

A rigorous mixed-methods research approach combining primary stakeholder interviews, documentary validation, and scenario stress testing to produce resilient strategic insights

The research underpinning this analysis combined structured primary engagement with industry stakeholders, rigorous secondary source synthesis, and scenario-based supply chain stress testing to ensure actionable and defensible insights. Primary engagement included interviews with senior leaders across development sciences, quality assurance, regulatory affairs, procurement, and operations from a spectrum of sponsor and contract manufacturing organizations. These conversations focused on capability gaps, recent investments, tech transfer experiences, and practical responses to policy or supply disruptions.

Secondary research reviewed regulatory guidance documents, technical white papers, and publicly available corporate disclosures to validate observed trends and to map capability footprints. Where possible, cross-referencing of production platform descriptions, facility audits, and filing histories was used to corroborate claims about service offerings and modality coverage. Scenario-based analysis simulated supply interruptions, tariff-induced cost shocks, and capacity loss events to evaluate the resilience of different sourcing configurations and contract structures.

Analytical methods included capability mapping across the segmentation dimensions, qualitative comparative analysis to identify differentiating practices among high-performing providers, and sensitivity testing of procurement and contracting levers under varying disruption scenarios. The research process emphasized triangulation, seeking concurrence across interview data, documentary evidence, and scenario outcomes to build robust conclusions while acknowledging uncertainty in policy trajectories and capital deployment timelines.

A concise synthesis of how capability integration, supply diversification, and modern contracting form the pillars of competitive resilience in contract manufacturing

The contractual and operational contours of pharmaceutical manufacturing are evolving rapidly under the influence of technological, regulatory, commercial, and geopolitical forces. Contract manufacturers that invest in platform versatility, advanced analytics, and digital controls will be best positioned to serve the complex needs of biologic and small-molecule sponsors alike. Strategic sourcing choices, inclusive of nearshoring and supplier diversification, have become critical levers to manage both cost and continuity risk, particularly in an environment where trade policy shifts can materially affect input economics.

Longer-term competitive advantage will accrue to organizations that can integrate development, analytical, and commercial manufacturing functions to minimize tech transfer friction and compress timelines. At the same time, strong governance over supplier origin and contractual mechanisms that transparently allocate input cost risk will be essential for preserving margins and maintaining reliable supply. The future will favor collaborative, partnership-oriented models that align incentives and create shared accountability for product quality and timely market access. Decision-makers who act decisively to fortify flexible capacity, codify contingency plans, and modernize contracting approaches will convert current disruption into durable strategic benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Contract Manufacturing Market, by Service Type

  • 8.1. Analytical Services
    • 8.1.1. Bioanalytical Services
    • 8.1.2. Method Development
    • 8.1.3. Stability Studies
  • 8.2. Development Services
    • 8.2.1. Formulation Development
    • 8.2.2. Process Development
  • 8.3. Filling Services
    • 8.3.1. Syringe Filling
    • 8.3.2. Unit Dose Filling
    • 8.3.3. Vial Filling
  • 8.4. Manufacturing Services
    • 8.4.1. Liquid Orals
    • 8.4.2. Solid Oral Dosage
    • 8.4.3. Sterile Injectables
    • 8.4.4. Topical Formulations
  • 8.5. Packaging & Labeling
    • 8.5.1. Primary Packaging
    • 8.5.2. Secondary Packaging

9. Pharmaceutical Contract Manufacturing Market, by Molecule Type

  • 9.1. Biologics
  • 9.2. Small Molecule

10. Pharmaceutical Contract Manufacturing Market, by Dosage Form

  • 10.1. Liquid Dosage
    • 10.1.1. Oral Solutions
    • 10.1.2. Suspensions
  • 10.2. Solid Dosage
    • 10.2.1. Capsules
    • 10.2.2. Tablets
  • 10.3. Sterile Injectables
  • 10.4. Topical Dosage
    • 10.4.1. Creams & Ointments
    • 10.4.2. Gels

11. Pharmaceutical Contract Manufacturing Market, by Therapeutic Area

  • 11.1. Cardiovascular
  • 11.2. CNS
  • 11.3. Infectious Diseases
  • 11.4. Oncology

12. Pharmaceutical Contract Manufacturing Market, by Contract Type

  • 12.1. Dedicated
  • 12.2. Non Dedicated

13. Pharmaceutical Contract Manufacturing Market, by Production Scale

  • 13.1. Clinical Trial
    • 13.1.1. Phase I
    • 13.1.2. Phase II
    • 13.1.3. Phase III
  • 13.2. Commercial

14. Pharmaceutical Contract Manufacturing Market, by Process Type

  • 14.1. Batch
  • 14.2. Continuous

15. Pharmaceutical Contract Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Pharmaceutical Contract Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Pharmaceutical Contract Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Pharmaceutical Contract Manufacturing Market

19. China Pharmaceutical Contract Manufacturing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Cambrex Corporation
  • 20.6. Catalent, Inc.
  • 20.7. Fujifilm Diosynth Biotechnologies US, LLC
  • 20.8. Lonza Group AG
  • 20.9. PCI Pharma Services, Inc.
  • 20.10. Recipharm AB
  • 20.11. Samsung Biologics Co., Ltd.
  • 20.12. Siegfried Holding AG
  • 20.13. Thermo Fisher Scientific Inc.
  • 20.14. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)

TABLE 27